Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes

Diabetes Care

Volumn 24, Issue 1, 2001, Pages 11-15

  Moses, Robert G ^a   Gomis, Ramon ^b   Frandsen, Kirstine Brown ^c   Schlienger, Jean Louis ^d   Dedov, Ivan ^e  

^a Wollongong Diabetes Service   (Australia)

^b HOSPITAL CLÍNIC   (Spain)

^c NOVO NORDISK A S   (Denmark)

^d HÔPITAL DE HAUTEPIERRE   (France)

^e N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; PLACEBO; REPAGLINIDE;

ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC DIET; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RANDOMIZED CONTROLLED TRIAL;

EID: 0035132989     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.24.1.11     Document Type: Article

References (20)

1. Pharmacokinetics and bioavailability of repaglinide, a new OHA for patients with NIDDM
2. Increased prandial insulin secretion following a single preprandial oral dose of repaglinide in patients with type 2 diabetes
3. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus
4. Insulin secretion and sensitivity in newly diagnosed NIDDM Caucasians in the UK
5. Repaglinide in type 2 diabetes: A 24-week, fixed-dose efficacy and safety study
6. A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes
7. Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes
8. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes: Dutch and German Repaglinide Study Group
9. A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas
10. Repaglinide compared to glipizide in the treatment of type 2 diabetic patients
11. Repaglinide versus glibenclamide: A one-year comparison trial
12. A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients
13. The effect of repaglinide on treatment satisfaction, well-being, and health status in type 2 diabetes patients
14. European NIDDM Policy Group: A desktop guide for the management of non-insulin-dependent diabetes mellitus (NIDDM): An update
15. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes
16. Rapid- and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia
17. Pharmacodynamics and dose response of nateglinide in type 2 diabetics
18. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
19. Prandial glucose regulation with repaglinide: Its clinical and lifestyle impact in a large cohort of patients with type 2 diabetes